Full notification fileGeneral informationNotification NumberB/ES/12/10Member State to which the notification was sentSpainDate of acknowledgement from the Member State Competent Authority31/01/2012Title of the ProjectSafety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv candidate HIV-1 vaccines in recently HIV-1 infected individuals with early viral suppression after initiation of antiretroviral therapy (HAART)Proposed period of release:01/06/2012 to 30/06/2013Name of the Institute(s) or Company(ies)IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Carretera de Canyet s/n
08916 Badalona (Barcelona);
3. Is the same GMO release planned elsewhere in the Community?NoHas the same GMO been notified elsewhere by the same notifier?YesIf yes, notification number(s): GMO characterizationGMO is a:DNA VirusIdentity of the GMO:The second genetically modified organism (GMO) used in the trial is the MVA.HIVconsv.
The MVA vector is a modified vaccinia Ankara virus, live recombinant, attenuated by serial passages in cultured chicken embryo fibroblasts (CEF) with contains six large deletions from the parental virus genome. To the MVA it has been inserted a transgene coding for the insert HIVconsv (as in the B/ES/12/09 ChAdV63.HIVconsv GMO) in order to induce an HIV-1 specific T cell immune response. The size of MVA.HIVconsv size after the insertion is estimated to be approximately 180 kbp.Information relating to the recipient or parental organisms from wich the GMO is derived
European Commission administrative informationConsent given by the Member State Competent Authority:Yes18/06/2012 00:00:00Remarks:
|MVA||Orthopox virus||vaccinia||-||Modified Virus Ankara||-|